1 year return (CAGR)
2660.63%
Active Biotech AB Exchange (ST, SEK)
ACTI.ST
4.03
-0.33 (-7.47%)
HealthcareBiotechnology
Loading...
3 year return (CAGR)
150.65%
5 year return (CAGR)
55.08%
10 year return (CAGR)
5.79%
Objective Corporation Stock Analysis – State Within State
Read MoreMarketcap
106.10M
Price/Sales
-
Ent value
72.90M
Price/Book
2.85
Div yield
0.00%
Growth years
-
Div growth
-
FCF payout
0.00%
Trailing P/E
-
PEG
-
Forward P/E
-
EPS growth
-16.59%
Stock information
What is a stock exchange? Operation, actors, examples
Read MoreStock chart
Loading...
Stock price data
| Open | 4.35 |
| Daily high | 4.35 |
| Daily low | 4.00 |
| Daily Volume | 86K |
| All-time high | 103.64 |
| 1y analyst estimate | 25.00 |
| Beta | 1.34 |
| EPS (TTM) | -1.27 |
| Dividend per share | 0.00 |
| Ex-div date | 17 Apr 1998 |
| Next earnings date | 7 May 2026 |
Downside potential
Loading...
Downside potential data
| ACTI.ST | S&P500 | |
| Current price drop from All-time high | -96.12% | -2.19% |
| Highest price drop | -99.96% | -56.47% |
| Date of highest drop | 18 Feb 2026 | 9 Mar 2009 |
| Avg drop from high | -92.38% | -10.69% |
| Avg time to new high | 3717 days | 12 days |
| Max time to new high | 7433 days | 1805 days |
News
Novartis added another failure to its docket Wednesday, dropping an experimental treatment for the muscle-wasting disease.
September 16, 2026
TG Therapeutics stock showed technical strength Wednesday, bounding off its 50-day moving average and nearing a breakout on the weekly chart.
September 16, 2026
Novo Nordisk and Anthropic strike a partnership to leverage Claude and other AI models in the drug development process.
September 16, 2026
BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- This morning, Trialynx was announced as the winner of DPHARM Idol Disrupt at the 16th annual DPHARM: Disruptive Innovations to Modernize Clinical Research 20...
September 16, 2026
Proceeds from the deal, which hands Novartis global rights to a technology developed by Sironax, will help advance three candidates that the startup says have “best-in-class” potential.
September 16, 2026
Suominen Corporation’s stock exchange release on September 16, 2026 at 6:30 p.m. (EEST) Changes in the Suominen Leadership Team As we continue to transform Suominen and strengthen our performance, we ...
September 16, 2026
Suominen Corporation’s stock exchange release, September 16, 2026 at 17:00 (EEST) Changes to Suominen Corporation’s share-based incentive plans for management and key employees and to the President & ...
September 16, 2026
Novartis exercises option to acquire Sironax’s brain delivery platform Sironax to advance three clinical-stage programs and multiple early-stage candidates using purchase proceeds Sironax to retain de...
September 16, 2026
Prostate cancer awareness spotlights Pfizer's Xtandi, Novartis' Pluvicto and clinical-stage programs from Candel and Janux.
September 16, 2026